AA
DBTX

AlphaCentric Advisors’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

AlphaCentric Advisors’s Portfolio DBTX Stock Details DBTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-37,500
Closed -$289K – 283
2021
Q3 		$289K Sell
37,500
-7,500
-17% -$57.2K 0.07% 96
2021
Q2 		$387K Buy
45,000
+36,000
+400% +$318K 0.11% 75
2021
Q1 		$102K Buy
+9,000
New +$141K 0.03% 153

Other funds holding DBTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $72.7B AUM 39.36% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

AlphaCentric Advisors's DBTX Position: Q4 2021 in Review

AlphaCentric Advisors sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q4 2021, closing a stake of 37,500 shares — an estimated $289K sold.

AlphaCentric Advisors first reported a position in DBTX in Q1 2021 and held it in 3 quarters. The position peaked at $387K in Q2 2021. 40 funds tracked by Wall St. Rank hold DBTX as of Q4 2021.

  • AlphaCentric Advisors reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • AlphaCentric Advisors sold 37,500 Decibel Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $289K.
  • AlphaCentric Advisors first reported a position in Decibel Therapeutics, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • AlphaCentric Advisors's Decibel Therapeutics, Inc. Common Stock position peaked at $387K in Q2 2021.
  • 40 funds tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.